AEBP2

Across TCGA pan-cancer cohorts, AEBP2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated AEBP2 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher AEBP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AEBP2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD, HNSC, and LSCC are the cancer types where AEBP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.402	0.871	.009	12	view →
HNSC	OS	Median	All	0.591	0.951	.005	10	view →
LSCC	OS	Tertile	II,III,IV	1.000	0.850	.005	8	view →
PDAC	OS	Median	All	0.353	0.690	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

AEBP2–LUAD (DFS)

Open the LUAD breakdown →